-

$undefined

N/A

(N/A)

Dogwood Therapeutics NasdaqCM:DWTX Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include Halneuron, which is in late-stage clinical development for the treatment of chemotherapy-induced neuropathic pain; IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia; and IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was incorporated in 2012 and is headquartered in Alpharetta, Georgia.

Location: 44 Milton Avenue, Alpharetta, GA, 30009, United States | Website: https://www.dwtx.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

69.93M

Cash

14.85M

Avg Qtr Burn

N/A

Short % of Float

13.46%

Insider Ownership

14.98%

Institutional Own.

7.95%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.